Skip to content

Quality of Life in Patients With Auto-inflammatory Diseases

Creation of a Tool to Assess Quality of Life in Patient With Auto-inflammatory Diseases

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03569644
Acronym
MAI-PATIENT
Enrollment
39
Registered
2018-06-26
Start date
2018-06-06
Completion date
2021-04-01
Last updated
2025-10-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hereditary Autoinflammatory Diseases

Brief summary

This qualitative interview-based study aim to build a tool to assess quality of life in patients (adults or children) suffering from 6 autoinflammatory diseases (FMF, TRAPS, CAPS, MKD, Still and PFAPA).

Detailed description

Recent understanding of the physiopathological mechanisms that underpin autoinflammatory diseases (AIDs) allowed a revolution in the therapeutic management of these patients, particularly through the use of biotherapies. However new treatments need to be evaluated by valid tools. AIDAI score created and validated by our team evaluates activity of 4 autoinflammatory diseases. One of the important components, not explored by the scores currently available, is the impact of these treatments on quality of life (QoL) of patients. The existing quality of life scales are not adapted to these recurrent chronic pathologies. Throught a qualitative study based on interviews of patients and/ or parents, the investigators aim to build a tool to evaluate QoL in patients suffering from 6 aAIDs :familial Mediterranean fever (FMF), mevalonate kinase deficiency (MKD), tumour necrosis factor receptor-associated periodic syndrome (TRAPS), cryopyrin-associated periodic syndromes (CAPS), Still's disease and PFAPA syndrome.

Interventions

Interviews

Sponsors

Assistance Publique - Hôpitaux de Paris
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE

Intervention model description

The study is based on interviews that will be recorded in digital audio and then transcribed literally. The consultation for this research is 45 to 90 minutes long. This prolongs their presence in consultation with the doctor. For this reason, the study was classified as Interventional according to French regulations

Eligibility

Sex/Gender
ALL
Healthy volunteers
No

Inclusion criteria

* Any patient (child and adult) with one of the 6 AIDs (FMF, TRAPS, MKD or CAPS, PFAPA or Still's disease) regardless of the activity of the disease. The diagnosis will have been made by the referring physician according to criteria specific to each AIDs * Volunteer to participate in the study * With at least one parent present at the consultation if it is a child under 18 years old * For minors, agreement of the parents or their legal representative or one of the present parents * Information for children as far as their age and condition allow * Affiliation to a national health insurance.

Exclusion criteria

* patient or relative (according to age)refuse to participate. * Bad understanding of French. * Other chronic inflammatory pathology associated (example: Crohn's, SPA, uveitis, psoriasis ...)

Design outcomes

Primary

MeasureTime frameDescription
Qualitative evaluation of quality of life by interviews of patients and/or parents45 to 90 minThe interviews will be recorded in digital audio and then transcribed literally. The analysis will be phenomenological. Four age group will be interviewed : \< 6 year-old (parents), 6 to 12 year-old (patients and parents) , 13 to 17 year-old (patients and parents) , \> 18 year-old (patients)

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026